European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMA/123152/2010
P/27/2010

EUROPEAN MEDICINES AGENCY DECISION

of 5 March 2010

on the acceptance of a modification of an agreed Paediatric Investigation Plan for pramipexole dihydrochloride (monohydrate) (Sifrol) (EMEA-000041-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13
E-mail: mail@ema.europa.eu http://www.ema.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 5 March 2010

on the acceptance of a modification of an agreed Paediatric Investigation Plan for pramipexole dihydrochloride (monohydrate) (Sifrol) (EMEA-000041-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the decision P/74/2008 of the European Medicines Agency on 12 September 2008,

Having regard to the application submitted by Boehringer Ingelheim International GmbH on 3 November 2009 under Article 22 of Regulation (EC) No 1901/2006 as amended proposing changes to the agreed Paediatric Investigation Plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 January 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to an agreed Paediatric Investigation Plan.

(2) It is therefore appropriate to adopt a Decision on the acceptance of changes to an agreed Paediatric Investigation Plan.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

Changes to the agreed Paediatric Investigation Plan for pramipexole dihydrochloride (monohydrate) (Sifrol), immediate release tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby accepted.

Article 2

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany**.**

Done at London, 5 March 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMA/PDCO/22743/2010
EMA-000041-PIP01-07-M01

OPINION OF THE PAEDIATRIC COMMITTEE ON THE ACCEPTANCE OF A MODIFICATION OF AN AGREED PAEDIATRIC INVESTIGATION PLAN

Scope of the application

Active substance(s):
Pramipexole dihydrochloride (monohydrate)

Invented name:
Sifrol

Condition(s):
Combined vocal and multiple motor tic disorder ("de la Tourette")
Restless Legs Syndrome

Pharmaceutical form(s):
Immediate Release Tablet

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Boehringer Ingelheim International GmbH

Information about the authorised medicinal product:
See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Boehringer Ingelheim International GmbH submitted to the European Medicines Agency on 3 November 2009 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/74/2008 of 12 September 2008. The application for modification proposed changes.

The procedure started on 19 November 2009.

Scope of the modification

Changes in some details of two studies performed for the condition "de la Tourette".

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13
E-mail: mail@ema.europa.eu http://www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes proposed by the applicant regarding the measures and the timelines of the paediatric investigation plan in the scope set out in Annex 1.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex and appendix.

London, 15 January 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S) / DISEASE(S)
Combined vocal and multiple motor tic disorder (de la Tourette)
Restless Legs Syndrome

B. WAIVER

- **Condition**

Combined vocal and multiple motor tic disorder (de la Tourette)

  - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:

Preterm newborn infants, Term newborn infants, Infants & toddlers and children less than 6 years, for immediate release tablets for oral use

- **Condition**

Restless Legs Syndrome

  - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:

Preterm newborn infants, Term newborn infants, Infants & toddlers and children less than 6 years, for immediate release tablets for oral use

C. PAEDIATRIC INVESTIGATION PLAN

C.1. Condition to be investigated

Combined vocal and multiple motor tic disorder (de la Tourette)

- **Subset(s) covered**

Children from 6 years old to less than 18 years

- **Formulation(s)**

Immediate release tablets for oral use
Paediatric strength of 0.0625mg shall be developed

C.2. Condition to be investigated

Restless Legs Syndrome

- **Subset(s) covered**

Children from 6 years old to less than 18 years

- **Formulation(s)**

Immediate release tablets for oral use
Paediatric strength of 0.0625mg shall be developed

- **Studies / Measures**

Area	Subarea	Number of studies	Description
Clinical	**PK dose finding. Efficacy and safety**	**1**	**Phase II, randomised, placebo-controlled, 6 week flexible dose study in children of 6 to 17 years with Tourette Syndrome**
Clinical	**Efficacy and safety**	**1**	**Phase III randomised, placebo controlled, 12 weeks fixed dose study in children of 6 to 17 years with Tourette Syndrome**
Clinical	**Efficacy and safety**	**1**	**Open label extension study of 6 to 17 years with Tourette Syndrome**
Clinical	**PK dose finding**	**1**	**Open label pharmacokinetic study of paediatric patients, 6 to 17 years with Restless Legs Syndrome**
Clinical	**Efficacy and safety**	**1**	**Randomised, double-blind, placebo-controlled, four parallel groups of paediatric patients, 6 to 17 years with Restless Legs Syndrome**

Need for paediatric measures in a EU-Risk Management Plan: Yes
Date of completion of the paediatric investigation plan: September 2013
A deferral has been granted: Yes

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/97/050/001	Sifrol	0.088 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/002	Sifrol	0.088 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/003	Sifrol	0.18 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/004	Sifrol	0.18 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/005	Sifrol	0.7 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/006	Sifrol	0.7 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/009	Sifrol	1.1 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/010	Sifrol	1.1 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/011	Sifrol	0.35 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/012	Sifrol	0.35 mg	Tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/013	Sifrol	0.26 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	10 tablets
EU/1/97/050/014	Sifrol	0.26 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/015	Sifrol	0.26 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/016	Sifrol	0.52 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	10 tablets
EU/1/97/050/017	Sifrol	0.52 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/018	Sifrol	0.52 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/019	Sifrol	1.05 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	10 tablets
EU/1/97/050/020	Sifrol	1.05 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/021	Sifrol	1.05 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/022	Sifrol	2.1 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	10 tablets
EU/1/97/050/023	Sifrol	2.1 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/024	Sifrol	2.1 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets
EU/1/97/050/025	Sifrol	3.15 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	10 tablets
EU/1/97/050/026	Sifrol	3.15 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	30 tablets
EU/1/97/050/027	Sifrol	3.15 mg	Prolonged-release tablet	Oral use	blister (polyamide/alu/PVC)	100 tablets